{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:03:58Z","timestamp":1790363038378,"version":"4.1.0"},"reference-count":36,"publisher":"Baskent University","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2020,8,10]]},"DOI":"10.6002\/ect.2019.0279","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T06:30:28Z","timestamp":1586759428000},"page":"444-449","source":"Crossref","is-referenced-by-count":11,"title":["Fabry Disease Screening in Patients With Kidney Transplant: A Single-Center Study in Turkey"],"prefix":"10.6002","volume":"18","author":[{"given":"Siyar","family":"Erdogmus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim","family":"Kutlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Ors Sendogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehsuvar","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Keven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulay","family":"Ceylaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Sengul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","unstructured":"1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"ref1","unstructured":"2. The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. http:\/\/www.hgmd.cf.ac.uk\/. Accessed March 30, 2019."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Koulousios K, Stylianou K, Pateinakis P, et al. Fabry disease due to D313Y and novel GLA mutations. BMJ Open. 2017;7(10):e017098.","DOI":"10.1136\/bmjopen-2017-017098"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Duro G, Zizzo C, Cammarata G, et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci. 2018;19(12).","DOI":"10.3390\/ijms19123726"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","unstructured":"5. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-346.","journal-title":"Ann Intern Med"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","unstructured":"6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254.","journal-title":"JAMA"},{"issue":"9","key":"ref6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","unstructured":"7. Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641-659.","journal-title":"QJM"},{"key":"ref7","unstructured":"8. Houge G, Skarbovik AJ. [Fabry disease--a diagnostic and therapeutic challenge]. Tidsskr Nor Laegeforen. 2005;125(8):1004-1006."},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","unstructured":"9. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-242.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","unstructured":"10. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47(4):217-222.","journal-title":"J Med Genet"},{"issue":"5","key":"ref10","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","unstructured":"11. Ortiz A, Oliveira JP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600-1607.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"ref11","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","unstructured":"12. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-2111.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000488121","article-title":"Fabry nephropathy: an evidence-based narrative review","volume":"43","author":"Del Pino","year":"2018","unstructured":"13. Del Pino M, Andres A, Bernabeu AA, et al. Fabry nephropathy: an evidence-based narrative review. Kidney Blood Press Res. 2018;43(2):406-421.","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"ref13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1159\/000452605","article-title":"The prevalence of Fabry disease in patients with chronic kidney disease in Turkey: The TURKFAB Study","volume":"41","author":"Turkmen","year":"2016","unstructured":"14. Turkmen K, Guclu A, Sahin G, et al. The prevalence of Fabry disease in patients with chronic kidney disease in Turkey: The TURKFAB Study. Kidney Blood Press Res. 2016;41(6):1016-1024.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/0886022X.2016.1254656","article-title":"Screening Fabry's disease in chronic kidney disease patients not on dialysis: a multicenter study","volume":"39","author":"Yenicerioglu","year":"2017","unstructured":"15. Yenicerioglu Y, Akdam H, Dursun B, et al. Screening Fabry's disease in chronic kidney disease patients not on dialysis: a multicenter study. Ren Fail. 2017;39(1):104-111.","journal-title":"Ren Fail"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","article-title":"Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation","volume":"527","author":"Okur","year":"2013","unstructured":"16. Okur I, Ezgu F, Biberoglu G, et al. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation. Gene. 2013;527(1):42-47.","journal-title":"Gene"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5414\/CN108672","article-title":"Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province","volume":"85","author":"Sayilar","year":"2016","unstructured":"17. Sayilar EI, Ayar Y, Yavuz M. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province. Clin Nephrol. 2016;85(3):165-172.","journal-title":"Clin Nephrol"},{"issue":"12","key":"ref17","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1093\/ndt\/gfn370","article-title":"Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients","volume":"23","author":"De Schoenmakere","year":"2008","unstructured":"18. De Schoenmakere G, Poppe B, Wuyts B, et al. Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrol Dial Transplant. 2008;23(12):4044-4048.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1432-2277.2008.00791.x","article-title":"Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria","volume":"22","author":"Kleinert","year":"2009","unstructured":"19. Kleinert J, Kotanko P, Spada M, et al. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int. 2009;22(3):287-292.","journal-title":"Transpl Int"},{"issue":"3","key":"ref19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.transproceed.2017.01.025","article-title":"Preliminary screening results of Fabry disease in kidney transplantation patients: a single-center study","volume":"49","author":"Yilmaz","year":"2017","unstructured":"20. Yilmaz M, Ucar SK, Asci G, et al. Preliminary screening results of Fabry disease in kidney transplantation patients: a single-center study. Transplant Proc. 2017;49(3):420-424.","journal-title":"Transplant Proc"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000496620","article-title":"Fabry disease prevalence in renal replacement therapy in Turkey","volume":"142","author":"Yalin","year":"2019","unstructured":"21. Yalin SF, Eren N, Sinangil A, et al. Fabry disease prevalence in renal replacement therapy in Turkey. Nephron. 2019;142(1):26-33.","journal-title":"Nephron"},{"issue":"9","key":"ref21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","unstructured":"22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308(1-2):195-196.","DOI":"10.1016\/S0009-8981(01)00478-8"},{"key":"ref23","unstructured":"24. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973;81(2):157-171."},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","unstructured":"25. Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant. 2013;28(3):505-517.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","unstructured":"26. van der Tol L, Smid BE, Poorthuis BJ, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1-9.","journal-title":"J Med Genet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/8904_2012_167","article-title":"Ala143Thr \"mutation\" in Fabry disease: implications for screening studies and ERT","volume":"8","author":"Terryn","year":"2013","unstructured":"27. Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr \"mutation\" in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101-108.","journal-title":"JIMD Rep"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","unstructured":"28. Lenders M, Weidemann F, Kurschat C, et al. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10897-017-0139-y","article-title":"the psychosocial impact of carrying a debated variant in the GLA gene","volume":"27","author":"Macklin","year":"2018","unstructured":"29. Macklin S, Laney D, Lisi E, Atherton A, Smith E. the psychosocial impact of carrying a debated variant in the GLA gene. J Genet Couns. 2018;27(1):217-224.","journal-title":"J Genet Couns"},{"issue":"6","key":"ref29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","unstructured":"30. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat. 2003;22(6):486-492.","journal-title":"Hum Mutat"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 Indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry Disease","volume":"7","author":"Niemann","year":"2013","unstructured":"31. Niemann M, Rolfs A, Giese A, et al. Lyso-Gb3 Indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry Disease. JIMD Rep. 2013;7:99-102.","journal-title":"JIMD Rep"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Oder D, Uceyler N, Liu D, et al. Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open. 2016;6(4):e010422.","DOI":"10.1136\/bmjopen-2015-010422"},{"issue":"3","key":"ref32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients","volume":"41","author":"Baptista","year":"2010","unstructured":"33. Baptista MV, Ferreira S, Pinho EMT, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41(3):431-436.","journal-title":"Stroke"},{"issue":"25","key":"ref33","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","unstructured":"34. Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-2403.","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2350-11-19","article-title":"Frequency of Fabry disease in male and female haemodialysis patients in Spain","volume":"11","author":"Gaspar","year":"2010","unstructured":"35. Gaspar P, Herrera J, Rodrigues D, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.","journal-title":"BMC Med Genet"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Lenders M, Duning T, Schelleckes M, et al. Multifocal white matter lesions associated with the D313Y mutation of the alpha-galactosidase A gene. PLoS One. 2013;8(2):e55565.","DOI":"10.1371\/journal.pone.0055565"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T05:01:31Z","timestamp":1597294891000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/current\/2020\/18\/4\/0\/444\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8,10]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2019.0279","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}